αAβ–Gas6 is a chimeric fusion protein being investigated for Alzheimer's disease. It is made of a single chain variable fragment (scFv) of an Amyloid β (Aβ)-targeting monoclonal antibody fused with a truncated receptor binding domain of growth arrest-specific 6 (Gas6), which is a ligand for receptor...
- Mechanism
- Curator reviewed · 6 references
TAM (TYRO3, AXL, and MERTK) receptors are receptor tyrosine kinases expressed ubiquitously, including microglia and astrocytes of the nervous system. They play a critical role in homeostatic processes such as phagocytosis of apoptotic cells and membranous organelles, and regulation of inflammatory responses and inflammation.
αAβ-Gas6 targets TAM receptors by binding to growth arrest-specific 6 (Gas6), a ligand for TAM receptors. By activating the TAM receptor signalling pathway, αAβ-Gas6 promotes TAM receptor-dependent phagocytosis to selectively eliminate Aβ plaques without affecting NF-kB-mediated inflammatory responses or reactive gliosis.
What you can answer from here — as of April 02, 2025
Which companies are running trials of αAβ–Gas6, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account